Gandhi Ronak, Kumar Padala Ravi, Pattanaik Sudhi R, Sahoo Devadarshini
Department of Endocrinology, MKCG Medical College and Hospital, Odisha, India.
Indian J Endocrinol Metab. 2022 Nov-Dec;26(6):565-574. doi: 10.4103/ijem.ijem_39_22. Epub 2023 Feb 7.
To study the effect of testosterone undecanoate on sexual functions, glycaemic parameters, and cardiovascular (CV) risk factors in hypogonadal men with type 2 diabetes mellitus (T2DM).
It was an open label, single-arm interventional study where testosterone undecanoate (TU) was used in 105 T2DM males aged 30-60 years with hypogonadism. The effect of TU on sexual functions was assessed using the Aging Male Symptoms (AMS) Scale and the International Index of Erectile Function-5 (IIEF-5) Questionnaire. The effect on glycaemic parameters, cardiovascular risk factors (lipids, high-sensitivity C-reactive protein [hsCRP] and carotid intima media thickness [CIMT]) were assessed over a period of 54 weeks of TU therapy.
Prevalence of hypogonadism in T2DM patients was 19.1%, of which 74.1% had functional hypogonadism. AMS and IIEF-5 scores showed negative and positive correlation, respectively, with baseline serum testosterone levels. The AMS score showed a significant reduction of 5.8% and IIEF-5 score improved by 31.5% at 54 weeks of TU therapy. Glycosylated hemoglobin (HbA1c), homeostatic model assessment for insulin resistance (HOMA-IR), and lipids such as total cholesterol (TC), low-density lipoprotein (LDL), and triglycerides (TG) were significantly reduced by 0.6%, 10.9%, 6.28%, 9.04%, and 6.77%, respectively, at 54 weeks. CIMT was significantly reduced by 2.57% at 54 weeks, whereas no significant change observed with hsCRP.
TU is an effective treatment modality for hypogonadal men with T2DM, and it has beneficial effects on sexual functions, glycaemic parameters, and CV risk factors.
研究十一酸睾酮对患有2型糖尿病（T2DM）的性腺功能减退男性的性功能、血糖参数和心血管（CV）危险因素的影响。
这是一项开放标签、单臂干预研究，105名年龄在30 - 60岁患有性腺功能减退的T2DM男性使用了十一酸睾酮（TU）。使用老年男性症状（AMS）量表和国际勃起功能指数-5（IIEF-5）问卷评估TU对性功能的影响。在TU治疗的54周期间评估对血糖参数、心血管危险因素（血脂、高敏C反应蛋白[hsCRP]和颈动脉内膜中层厚度[CIMT]）的影响。
T2DM患者中性腺功能减退的患病率为19.1%，其中74.1%为功能性性腺功能减退。AMS和IIEF-5评分分别与基线血清睾酮水平呈负相关和正相关。在TU治疗54周时，AMS评分显著降低了5.8%，IIEF-5评分提高了31.5%。糖化血红蛋白（HbA1c）、胰岛素抵抗稳态模型评估（HOMA-IR）以及总胆固醇（TC）、低密度脂蛋白（LDL）和甘油三酯（TG）等血脂在54周时分别显著降低了0.6%、10.9%、6.28%、9.04%和6.77%。CIMT在54周时显著降低了2.57%，而hsCRP未观察到显著变化。
TU是治疗患有T2DM的性腺功能减退男性的有效治疗方式，并且对性功能、血糖参数和CV危险因素具有有益影响。
